Last reviewed · How we verify

NCT02784730: PICC One Day

Iterative PICC Placement Versus Long Term Device

Withdrawn Phase 3 Last updated 5 February 2018
What this trial tests

Phase 3 trial testing Iterative PICC placement in Breast Cancer. Withdrawn.

Timeline
10 January 2018
Primary endpoint
10 January 2018
10 January 2018

Quick facts

Lead sponsorCentre Leon Berard
PhasePhase 3
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeother
Start date10 January 2018
Primary completion10 January 2018
Estimated completion10 January 2018
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Leon Berard — full company profile →

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Peripherally Inserted Central Catheter (PICC) and port-a-cath (PAC) are the most commonly medical devices used for the administration of chemotherapy. Placement of these devices via central venous access is sometimes responsible for complications. The incidence of these complications is correlated with the device holding time. A strategy of iterative PICC placement could significantly reduce these complications.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

Other Centre Leon Berard trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02784730.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing